CoChat
Sign Up
Cited by 53

The DOI matches its Crossref record.

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Mughal, Tariq·2010·Biologics: Targets & Therapy
DOI 10.2147/btt.s5775PMC PMC3010822
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/btt.s5775

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 70

  1. [1]Buchdunger E Zimmermann J Mett H Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class Proc Natl Acad Sci U S A 1995 92 2558 2562 7708684 PMC42257
  2. [2]Druker BJ Tamura S Buchdunger E Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 1996 2 561 566 8616716
  3. [3]Heinrich MC Griffith DJ Druker BJ Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 2000 96 925 932 10910906
  4. [4]Deininger MW O’Brien SG Ford JM Druker BJ Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol 2003 21 1637 1647 12668652
  5. [5]Druker BJ Guilhot F O’Brien SG Five-year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemia N Engl J Med 2006 355 2408 2417 17151364
  6. [6]Mughal TI Goldman JM Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007 Clin Lymphoma Myeloma 2007 7 338 339 17382023
  7. [7]Hochhaus A O’Brien SG Guilhot F Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 2009 213 1054 1061 19282833
  8. [8]Kantarjian H Talpaz M O’Brien S High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia Blood 2004 103 2873 2878 15070658
  9. [9]Hughes TP Branford S White DL Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy Blood 2008 112 3965 3973 18768781
  10. [10]Cortes JE Baccarani M Guilhot F Phase III. Randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 2010 28 424 430 20008622 PMC4979244
  11. [11]Kerkela R Grazette L Yacobi R Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 2006 12 908 916 16862153
  12. [12]Schiffer CA BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia N Engl J Med 2007 357 258 265 17634461
  13. [13]Atallah E Kantarjian H Cortes J In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’ Nat Med 2007 13 14 author reply 15–16. 17206119
  14. [14]Rosti G Martinelli G Baccarani M In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’ Nat Med 2007 13 15 author reply 15–16. 17206121
  15. [15]Schmidinger M Zielinski CC Vogl UM Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 2008 26 5204 5212 18838713
  16. [16]Park YH Park HJ Kim BS BNP as a marker of the heart failure in the treatment of imatinib mesylate Cancer Lett 2006 243 16 22 16388897
  17. [17]Atallah E Durand JB Kantarjian H Cortes J Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 2007 110 1233 1237 17449798
  18. [18]Ribeiro AL Marcolino MS Bittencourt HN An evaluation of the cardiotoxicity of imatinib mesylate Leuk Res 2008 32 1809 1814 18495246
  19. [19]Perik PJ Rikhof B de Jong FA Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Ann Oncol 2008 19 359 361 17962203
  20. [20]Tiribelli M Colatutto A Marin L Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy Am J Hematol 2008 83 517 518 18306359
  21. [21]Berman E Nicolaides M Maki RG Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 2006 354 2006 2013 16687713
  22. [22]Liu F Malaval L Aubin JE Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation J Cell Sci 2003 116 1787 1796 12665559
  23. [23]Hock JM Canalis E Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts Endocrinology 1994 134 1423 1428 8119182
  24. [24]Fiedler J Etzel N Brenner RE To go or not to go: migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF J Cell Biochem 2004 93 990 998 15389881
  25. [25]Grey A O’Sullivan S Reid IR Browett P Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism N Engl J Med 2006 355 2494 2495 17151376
  26. [26]O’Sullivan S Horne A Wattie D Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib J Clin Endocrinol Metab 2009 94 1131 1136 19174494
  27. [27]Tibullo D Giallongo C La Cava P Effects of imatinib mesylate in osteoblastogenesis Exp Hematol 2009 37 461 468 19302920
  28. [28]Fitter S Dewar AL Kostakis P Long-term imatinib therapy promotes bone formation in CML patients Blood 2008 111 2538 2547 18042796
  29. [29]Frédéric M Baruchel A Guilhot J Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CNL) in early chronic phase (CP): results of the French National Phase IV trial ASH proceedings; 2009; [Abstract 863].
  30. [30]Schwartzberg PL Stall AM Hardin JD Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations Cell 1991 65 1165 1175 2065353
  31. [31]Ault P Kantarjian H O’Brien S Pregnancy among patients with chronic myeloid leukemia treated with imatinib J Clin Oncol 2006 24 1204 1208 16446320
  32. [32]Pye SM Cortes J Ault P The effects of imatinib on pregnancy outcome Blood 2008 111 5505 5508 18322153 PMC4916938
  33. [34]Martin H van der Kuip Heiko Walter EA Therapeutic options for chronic myeloid leukemia: focus on imatinib Ther Clin Risk Manag 2008 4 163 187 18728706 PMC2503652
  34. [35]Gambacorti-Passerini C Tornaghi L Cavagnini F Gynaecomastia in men with chronic myeloid leukaemia after imatinib Lancet 2003 361 1954 1956 12801741
  35. [36]Hawk K Heung-Moon C Min-Hee R Tae-Won K Hee-Jung S So-Eun K Concurrent male gynecomastia and testicular hydrocele after imatinibmesylate treatment of a gastrointestinal stromal tumor J Korean Med Sci 2005 20 512 515 15953881 PMC2782215
  36. [37]Mannavola D Coco P Vannucchi G A novel tyrosine kinase inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake J Clin Endocrinol Metab 2007 92 3531 3534 17595247
  37. [38]Tamaskar I Bukowski R Elson P Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib Ann Oncol 2008 19 265 268 17962201
  38. [39]Torino F Corsello S Longo R Hupothyroidism related to tyrsoine kinase inhibitors: an emerging toxic effect on targeted therapy Nat Rev Clin Oncol 2009 6 219 228 19333228
  39. [40]de Groot JW Zonnenberg BA Plukker JT van Der Graaf WT Links TP Imatinib induces hypothyroidism in patients receiving levothyroxine Clin Pharmacol Ther 2005 78 433 438 16198662
  40. [41]Mustjoki S Ekblom M Arstila TP Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Leukemia 2009 23 1398 1405 19295545
  41. [42]Santachiara R Maffei R Martinelli S Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor Haematologica 2008 93 1252 1255 18519520
  42. [43]Senn L Kovacsovics T Tarr PE Meylan P Peritoneal tuberculosis after imatinib therapy Arch Intern Med 2009 169 312 313 19204223
  43. [44]Ogasawara M Matsukawa T Katsura Y Imatinib impairs the function of human regulatory T cells (Tregs) and reverses the inhibition of immune responses to imatinib-resistant CML cells by Tregs ASH Meeting Proceedings 2009 12 1114 4728
  44. [45]Van Glabbeke M Verweij J Casali PG Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) Eur J Cancer 2006 42 2277 2285 16876399
  45. [46]Larson RA Druker BJ Guilhot F Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 2008 111 4022 4028 18256322
  46. [47]Brouard M Saurat JH Cutaneous reactions to STI571 N Engl J Med 2001 345 618 619 11529225
  47. [48]Hsiao LT Chung HM Lin JT Stevens-Johnson syndrome after treatment with STI571: a case report Br J Haematol 2002 117 620 622 12028031
  48. [49]Nelson RP Jr Cornetta K Ward KE Desensitization to imatinib in patients with leukemia Ann Allergy Asthma Immunol 2006 97 216 222 16937754
  49. [50]Park MA Volcheck GW Guarderas JC Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature Allergy Asthma Proc 2004 25 345 347 15603208
  50. [51]Rule SA O’Brien SG Crossman LC Managing cutaneous reactions to imatinib therapy Blood 2002 100 3434 3435 12412577
  51. [52]Gambillara E Laffitte E Widmer N Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia Dermatology 2005 211 363 365 16286749
  52. [53]Severino G Chillotti C De Lisa R Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors Ann Pharmacother 2005 39 162 164 15546944
  53. [54]Raanani P Goldman JM Ben-Bassat I Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571 J Clin Oncol 2002 20 869 870 11821474
  54. [55]Valeyrie L Bastuji-Garin S Revuz J Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients J Am Acad Dermatol 2003 48 201 206 12582389
  55. [56]Arora B Kumar L Sharma A Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate Ann Oncol 2004 15 358 359 14760137
  56. [57]Etienne G Cony-Makhoul P Mahon FX Imatinib mesylate and gray hair N Engl J Med 2002 347 446 447 12167692
  57. [58]Talpaz M Silver RT Druker BJ Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 2002 99 1928 1937 11877262
  58. [59]Lin NU Sarantopoulos S Stone JR Fatal hepatic necrosis following imatinib mesylate therapy Blood 2003 102 3455 3456 14568907
  59. [60]Ferrero D Pogliani EM Rege-Cambrin G Corticosteroids can reverse severe imatinib-induced hepatotoxicity Haematologica 2006 91 35 37 16785130
  60. [61]Ohnishi K Sakai F Kudoh S Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate Leukemia 2006 20 1162 1164 16598305
  61. [62]Roy L Guilhot J Martineau G Larchée R Guilhot F Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia Leukemia 2005 19 1689 1692 16015386
  62. [63]Pilot PR Sablinska K Owen S Hatfield A Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib Leukemia 2006 20 148 16292349
  63. [64]Cortes J O’Dwyer ME Clonal evolution in chronic myelogenous leukemia Hematol Oncol Clin North Am 2004 18 671 684 15271399
  64. [65]Terre C Eclache V Rousselot P Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia Leukemia 2004 18 1340 1346 15190256
  65. [66]Medina J Kantarjian H Talpaz M Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Cancer 2003 98 1905 1911 14584073
  66. [67]Kovitz C Kantarjian H Garcia-Manero G Abruzzo LV Cortes J Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia Blood 2006 108 2811 2813 16809614
  67. [68]Jabbour E Kantarjian HM Abruzzo LV Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase Blood 2007 110 2991 2995 17625066
  68. [69]Ebnöether M Stentoft J Ford J Buhl L Gratwohl A Cerebral edema as a possible complication of treatment with imatinib Lancet 2002 359 1751 1752 12049868
  69. [70]Goldman JM Mughal TI Chronic Myeloid Leukemia Hoffbrand Tuttenham Catovsky Oxford, UK Blackwell Science 2005
  70. [71]Valsamis HA Antiepileptic drugs and bone metabolism Nutr Metab 2006 3 36 doi:10.1186/1743-7075-3-36. PMC1586194 16956398 · DOI

Cited by

Sorted by citations

See all 53

Metadata

Authors
Mughal, T.
Venue
Biologics: Targets & Therapy
Publisher
Informa UK Limited
Published
2010-12
Pages
315
ISSN
1177-5475
DOI
10.2147/btt.s5775
PMC
PMC3010822
Cited by
53
References
0
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. https://app.cochat.ai/papers/10.2147/btt.s5775
The paper
Mughal, T. (2010). Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics: Targets & Therapy. https://doi.org/10.2147/btt.s5775